Medical significance of endothelial glycocalyx;Importancia médica del glucocáliz endotelial

Archivos de Cardiologia de Mexico

Volumn 83, Issue 4, 2013, Pages 303-312

  Frati Munari, Alberto C ^a  

^a LIVER RESEARCH UNIT   (Mexico)

Author keywords

Atherosclerosis; Chronic venous disease; Endothelial dysfunction; Glycocalyx; Mexico; Sulodexide

Indexed keywords

GLYCOPROTEIN; GLYCOSAMINOGLYCAN; LIPOPROTEIN; PROTEOGLYCAN; REACTIVE OXYGEN METABOLITE;

ARGON PLASMA COAGULATION; ARTICLE; BLOOD CLOTTING; BLOOD VESSEL PERMEABILITY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL GLYCOCALYX; ENDOTHELIUM CELL; FIBRINOLYSIS; GLYCOCALYX; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERNATREMIA; MECHANOTRANSDUCTION; SHEAR STRESS; VASCULAR DISEASE; METABOLIC DISEASES; PHYSIOLOGY; ULTRASTRUCTURE; VASCULAR DISEASES; VASCULAR ENDOTHELIUM;

ENDOTHELIUM, VASCULAR; GLYCOCALYX; HUMANS; METABOLIC DISEASES; VASCULAR DISEASES;

EID: 84890032494     PISSN: 14059940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acmx.2013.04.015     Document Type: Short Survey

References (82)

1. Echandi K, Hernández F. Comparación de dos métodos de fijación para la estabilización de glicocalix bacteriano. Rev Biomed. 1998;9, 1-7.
2. Behnke O. Electron microscopical observations on the surface coating of human platelets. J Ultrastruct Res. 1968;24:51-69.
3. O'Brien JR. Some effects of mucopolysaccharide stains on platelet aggregation. J Clin Path. 1970;23:784-8.
4. Boom A, Daems WTh, Luft JH. On the fixation of intestinal absorptive cells. J Ultrastruct Res. 1974;48:350-60.
5. Rosenfeld C, Paintrand U, Choquet C, et al. Cyclic variations in the ruthenium red stained coat cells from a synchronized human lymphoblastoid line. Exp Cell Res. 1973;79:465-8.
6. Maksimenko AV, Turashev AD. No-reflow phenomenon and endothelial glycocalyx of microcirculation. Biochem Res Int. 2012;2012:859231.http://dx.doi.org/10.1155/2012/859231.
7. Loscalzo J. Nitric oxide and vascular disease. N Engl J Med. 1995;333:251-3.
8. Deanfield J, Donald A, Ferri C, et al. Endothelial function and dysfunction. Part I. Methodological issues for assessment in the different vascular beds: A statement by Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hyperten. 2005;23:7-17.
9. Zhang DX, Gutterman DD. Mitochondrial reactive speciesmediated signaling in endothelial cells. Am J Physiol Heart CircPhysiol. 2006;292:H2023-31.
10. VerdejoParís J. Función endotelial. Arch Cardiol Mex. 2006;76(S2):S164-9.
11. Ghiadoni L, Versari D, Giannarelli C, et al. Non-invasive diagnostic tools for investigating endothelial dysfunction. Curr Pharm Des. 2008;14:3715-22.
12. Celermajer DS, Sorensen KE, Bull C, et al. Endotheliumdependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol. 1994;15:1468-74.
13. Vanhoutte P. Ageing and endothelial dysfunction. Eur Heart J. 2004;4 Suppl A:A8-17.
14. Seller AM, Schachinger V, Minners J. Long-term cigarette smoking impairs endothelium-dependent coronary artery vasodilator function. Circulation. 1995;92:1094-110.
15. Quyyumi AA, Mulcahy D, Andrews NP, et al. Coronary vascular nitric oxide activity in hypertension and hypercholesterolemia. Comparison of acetylcholine and substance P. Circulation. 1997;95:104-10.
16. Brunner H, Cockcroft JR, Deanfield J, et al. Endothelial function and dysfunction. Part II. Association with cardiovascular risk factors and diseases. A statement by Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens. 2005;23:233-46.
17. Tani C, Mosca M, d'Ascanio A, et al. [Chronic inflammation and endothelial dysfunction: An analysis of a cohort of patients with SLE and UCTD]. Reumatismo. 2006;58:212-8.
18. Neunteufl T, Katzenschlager R, Hassan A, et al. Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. Atherosclerosis. 1997;129:111-8.
19. Brownlee M. The pathobiology of diabetic complications. A unifying mechanism. Diabetes. 2005;54:1615-25.
20. Higashi Y, Noma K, Yoshizumi M, et al. Endothelial function and oxidative stress in cardiovascular diseases. Circ J. 2009;73:411-8.
21. Avogaro A, Fadini GP, Gallo A, et al. Endothelial dysfunction in type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis. 2006;16 Suppl 1:S39-45.
22. Kavalliede JC, Gnudi L. Endothelial factors and diabetic nephropathy. Diabetes Care. 2011;34 suppl 2:S291-6.
23. Saharay M, Shields DA, Georgiannos SN, et al. Endothelial activation in patients with chronic venous disease. Eur J Vasc Endovasc Surg. 1998;15:342-9.
24. Nash GB, Buckley CD, Rainger GE. The local physicochemical environment conditions the proinflammatory response of endothelial cells and thus modulates leukocyte recruitment. FEBS Letters. 2004;569:13-7.
25. Luft JH. Fine structure of capillary and endocapillary layer as revealed by ruthenium red. Fed Proc. 1966;25:1773-83.
26. Van den Bergh BM, Vink H, Spaan JA. The endothelial glycocalyx protects against myocardial edema. Circ Res. 2003;92:592-4.
27. Reitsma S, Slaaf DW, Vink H, et al. The endothelial glycocalyx: Composition, functions, and visualization. Pflugers Arch. 2007;454:345-59.
28. Ben WY, Cai B, Zeng M, et al. Quantification of the endothelial surface glycocalyx on rat and mouse blood vessel. Microvasc Res. 2012;83:337-46.
29. Bai K, Wang W. Spatio-temporal development of the endothelial glycocalyx layer and its mechanical property in vitro. J Roy Soc Interface. 2012. http://dx.doi.org/10-1098/srif.2011.0901.
30. Nieuwdorp M, Meuwese MC, Mooij HL, et al. Measuring endothelial glycocalyx dimensions in humans: A potential novel tool to monitor vascular vulnerability. J Appl Physiol. 2008;104:845-52.
31. Nieuwdorp M, Meuwese MC, Vink H, et al. The endothelial glycocalyx: A potential barrier between health and vascular disease. Curr Opin Lipidol. 2005;16:507-11.
32. Tarbell JM, Pahakis MY. Mechanotransduction and glycocalyx. J Intern Med. 2006;259:339-50.
33. Becker BF, Chappell D, Bruegger D, et al. Therapeutic strategies targeting the endothelial glycocalyx: Acute deficits, but great potential. Cardiovasc Res. 2010;87:300-10.
34. Florian JA, Kosky JR, Ainslie K, et al. Heparan sulfate proteoglycan is a mechanosensor on endotelial cells. Circ Res. 2003;93:e136-42.
35. Mochizuki S, Vink H, Hiramatsu O, et al. Role of hyaluronic acid glycosaminoglycans in shear-induced endothelium-derived nitric oxide release. Am J Physiol Heart Circ Physiol. 2003;285:H722-6.
36. Thi MM, Tarbell JM, Weinbaum S, et al. The role of the glycocalyx in reorganization of the actin cytoskeleton under fluid shear stress: A bumper-car model. PNAS. 2004;101:16483-8.
37. Arisaka T, Mitsumata M, Kawasumi M, et al. Effects of shear stress on glycosaminoglycan syntesis in vascular endothelial cells. Ann NY Acad Sci. 1995;748:543-54.
38. Governeur M, van den Berg B, Nieuwdorp M, et al. Vasculoprotective properties of the endothelial glycocalyx: Effects of fluid shear stress. J Intern Med. 2006;259:393-400.
39. Barakat AI. Dragging along: The glycocalyx and vascular endothelial cell mechanotransduction. Circ Res. 2008;102: 747-8.
40. Lopez-Quintero SV, Amaya R, Pahakis M, et al. The endothelial glycocalyx mediates shear-induced changes in hydraulic conductivity. Am J Physiol Heart Circ Physiol. 2009;296:H1451-6.
41. Van Haaren PMA, van Bavel E, Vink H, et al. Localization of the permeability barrier to solutes in isolated arteries by confocal microscopy. Am J Physiol Heart Circ Physiol. 2003;285:H2848-56.
42. Huxley HH, Williams DA. Role of a glycocalyx on coronary arteriole permeability to proteins: Evidence from enzyme treatments. Am J Physiol Heart Circ Physiol. 2000;278:H1177-85.
43. Jacob M, Bruegger D, Rehm M, et al. The endothelial glycocalyx affords compatibility of Starling's principle and high cardiac interstitial albumin levels. Cardiovasc Res. 2007;73:575-86.
44. Van Haaren PMA, vanBavel E, Vink H, et al. Charge modification of endothelial surface layer modulates the permeability barrier of isolated rat mesenteric small arteries. Am J Physiol Heart Circ Physiol. 2005;289:H2503-7.
45. Oberleithner H, Peters W, Kusche-Vihrog K, et al. Salt overload damages the glycocalyx sodium barrier of vascular endothelium. Pflugers Arch. 2011;462:519-28.
46. Kusche-Vihrog K, Oberleithner H. An emerging concept of vascular salt sensitivity. F1000 Biol Rep. 2012;4:20. http://dx.doi.org/10.3410/B4-20.
47. Rostgaard J, Qvortrup K. Electron microscopic demonstrations of filamentous molecular sieve plugs in capillary fenestrae. Microvasc Res. 1997;53:1-13.
48. Rostgaard J, Qvortrup K. Sieve plugs in fenestrae of glomerular capillaries-site of filtration barrier. Cells Tissue Organs. 2002;170:132-8.
49. Haraldsson B, Sörensson J. Why do not all have proteinuria? An update of our current understanding of glomerular barrier. Physiology. 2004;19:7-10.
50. Desjardins C, Duling BR. Heparinase treatment suggests a role for the endothelial cell glycocalyx in regulation of capillary hematocrit. Am J Physiol Heart Circ Physiol. 1990;258:H647-54.
51. Zuurbier CJ, Demirci C, Koeman A, et al. Short-term hyperglycemia increases endothelial glycocalyx permeability and acutely decreases lineal density of capillaries with flowing red blood cells. J Appl Physiol. 2005;99:1471-6.
52. Mulivor AW, Lipowsky HH. Role of glycocalyx in leukocyteendothelial cell adhesion. Am J Physiol Heart Circ Physiol. 2002;283:H1282-91.
53. Constantinescu AA, Vink H, Spaan JAE. Endothelial cell glycocalyx modulates immobilization of leukocytes at the endothelial surface. Arterioscler Thromb Vasc Biol. 2003;23:1541-7.
54. Butler LM, Rainger GE, Nash GB. A role for the endothelial glycosaminoglycan hyaluronan in neutrophil recruitment by endothelial cells cultured for prolonged periods. Exp Cell Res. 2009;315:3433-41.
55. Henry CBS, Duling BR. TNF-α increases entry of macromolecules into luminal endothelial cell glycocalyx. Am J Physiol Heart Circ Physiol. 2000;279:H2815-23.
56. Lipowsky HH. Protease activity and the role of the endothelial glycocalyx in inflammation. Drug Discov Today Dis Models. 2011;8:57-62.
57. Mulivor AW, Lipowsky HH. Inflammation -and ischemia- induced shedding of venular glycocalyx. Am J Physiol Heart Circ Physiol. 2004;286:H1672-80.
58. Mulivor AW, Lipowsky HH. Inhibition of glycan shedding and leukocyte- endothelial adhesion in postcapillary venules by suppression of matrix metalloprotease activity with doxycycline. Microcirculation. 2009;16:657-66.
59. Lipowsky HH, Gao L, Lescanic A. Shedding of the endothelial glycocalyx in arterioles, capillaries, and venules and its effect on capillary hemodynamics during inflammation. Am J Physiol Heart Circ Physiol. 2011;301:H2235-45.
60. Rubio-Gayosso I, Platts SH, Duling BR. Reactive oxygen species mediate modification of glycocalyx during ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2006;290:H2247-56.
61. Moseley R, Waddington RJ, Embery G. Degradation of glycosaminoglycans by reactive oxigen species derived from stimulated polymorfonucleal leukocytes. Biochem Biophys Acta. 1997;1362:221-31.
62. Rehm M, Bruegger D, Christ F, et al. Shedding of the endothelial glycocalyx in patients undergoing major vascular surgery with global and regional ischemia. Circulation. 2007;116:1896-906.
63. Gershov D, Kim S, Brot N, et al. C-reactive protein bind to apotptotic cells, protect the cells from assembly of terminal complement components, and sustains an anti-inflammatory innate immune response: Implication for systemic autoimmunity. J Exper Med. 2000;192:1353-63.
64. Barret TD, Hennan JK, Marks RM, et al. C-reactive-proteinassociated increase in myocardial infarct size after ischemia/ reperfusion. J Pharmacol Exp Ther. 2002;303:1007-13.
65. Lauver DA, Booth EA, White AJ, et al. Sulodexide attenuates myocardial ischemia/reperfusion injury and the deposition of C-reactive protein in areas of infarction without affecting hemostasis. J Pharmacol Exp Ther. 2005;312:794-800.
66. Mellbin LG, Bjerre M, Thiel S, et al. Complement activation and prognosis in patients with type 2 diabetes and myocardial infarction. A report from DIGAMI 2 trial. Diabetes Care. 2012;35:911-7.
67. Iacoviello LD. Ádamo MC, Pawlak K, et al. Antithrombotic activity of dermatan sulphates, heparins and their combination in animal model of arterial thrombosis. Thromb Haemost. 1996;76:1102-7.
68. Trowbridge JM, Gallo RL. Dermatan sulfate: New functions from an old glycosaminoglycan. Glycobiology. 2002;12:117R-25R.
69. Tovar AM, de Mattos DA, Stelling MP, et al. Dermatan sulfate is the predominant antithrombotic glycosaminoglycan in vessel walls: Implications for a posible physiological function of heparin cofactor II. Biochem Biophys Acta. 2005;15: 45-53.
70. He L, Giri TK, Vicente CP, et al. Vascular dermatan sulfate regulates the antithromboytic activity of heparin cofactor II. Blood. 2008;111:4118-25.
71. Tollefsen DM. Heparin cofactor II modulates the response to vascular injury. Arterioscler Thromb Vasc Biol. 2007;27:54-460.
72. Rosemberg RD, Shworak NW, Liu J, et al. Heparan sulfate proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis regulated? J Clin Invest. 1997;100:S67-75.
73. Constantinescu AA, Spaan JAE, Arkenbout EK, et al. Degradation of the endotelial glycocalyx is associated with chylomicron leakage in mouse cremaster muscle microcirculation. Thromb Haemost. 2011;105:790-801.
74. Vink H, Constantinescu AA, Spaan JAE. Oxidized lipoproteins degrade the endothelial surface layer. Implications for plateletendothelial cell adhesion. Circulation. 2000;101:1500-2.
75. Meuwese MC, Mooij HL, Nieuwdorp M, et al. Partial recovery of the endothelial glycocalyx upon rosuvastatin therapy in patients with heterozygous familial hypercholesterolemia. J Lipid Res. 2009;50:148-53.
76. Van den Berg BM, Spaan JAE, Tolf TM, et al. Atherogenic region and diet diminish glycocalyx dimension and increase intima-tomedia ratios at murine carotid artery bifurcation. Am J Physiol Heart Circ Physiol. 2006;290:H915-20.
77. Kelly R, Ruane-O'Hora T, Noble MIM, et al. Differential inhibition by hyperglycaemia of shear stress- but not acetylcholinemediated dilatation in the artery of anaesthetized pig. J Physiol. 2006;573:133-45.
78. Zuurbier CJ, Demirci C, Koeman A, et al. Short term hyperglycemia increases endothelial glycocalyx permeability and acutely decreases lineal density of capillaries with flowing red blood cells. J Appl Physiol. 2005;99:1471-6.
79. Nieuwdorp M, van Haeften TW, Gouverneur MCLG, et al. Loss of endotelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. Diabetes. 2006;55:480-6.
80. Lucas-Luciardi H, Berman SG, Chain S, et al. Determinación de marcadores séricos de trombosis e inflamación en sujetos con intolerancia a la glucosa: evidencia de un estado protrombótico. Arch Cardiol Mex. 2012;82:1-6.
81. Nieuwdorp M, Mooij HL, Kroon J, et al. Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes. 2006;55:1127-32.
82. Broekhuizen LN, Lemkes BA, Mooij HL, et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia. 2010;53:2646-55.